Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Refractory Primary Bone Tumors
2024-514720-17-00Phase 2Authorised
- Sponsor
- Institute of Mother and Child
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of regorafenib in osteosarcoma (OS) and Ewing sarcoma, sponsored by Institute of Mother and Child. Primary endpoints: Event-Free Survival (EFS), Dose determination for 9–18 year-old patients and 2 more. Planned start Aug 2024; status: authorised.
02
Drugs
regorafenib
03
Conditions
osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on 2024-514720-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514720-17-00.